Full text is available at the source.
Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice
Activating glucagon-like peptide-1 receptors improves metabolism and liver health in mice with fatty liver disease
AI simplified
Abstract
AC3174 treatment led to significant reductions in body weight (8.3%), liver mass (14.2%), and liver lipid (12.9%) in mice fed a high trans-fat diet.
- High lard fat diet resulted in larger weight gains and fat accumulation in mice compared to the high trans-fat diet.
- The high trans-fat diet better represented key features of nonalcoholic steatohepatitis (NASH), including liver enlargement and fibrosis.
- GLP-1 receptor activation with AC3174 improved liver health indicators in both Lep(ob)/Lep(ob) and C57BL6J mice on different diets.
- Weight loss alone was not solely responsible for AC3174's liver health benefits, as a calorie-restricted group showed only minor effects.
- GLP-1 receptor deficiency in mice negated the beneficial effects of AC3174 on body weight and liver health.
- The GLP-1 receptor's role in NASH warrants further investigation, as GLP-1 receptor-deficient mice showed protection from high trans-fat diet effects.
AI simplified